Will Increasing the Term of Data Exclusivity for Biologic Drugs in the TPP Reduce Access to Medicines?

The following guest post comes from Philip Stevens, Director of the Geneva Network, a research and advocacy organization working on international health, trade, and intellectual property issues. The original research note can be found here. By Philip Stevens In the Trans-Pacific Partnership (TPP) negotiations, the U.S. and Japan have proposed that TPP partners increase their … Continue reading “Will Increasing the Term of Data Exclusivity for Biologic Drugs in the TPP Reduce Access to Medicines?”